Navigation Links
deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers
Date:9/25/2011

REYKJAVIK, Iceland, September 25, 2011 /PRNewswire/ --

Scientists at deCODE Genetics and academic collaborators from Iceland, The Netherlands, Spain, Denmark, Germany, Sweden, the USA, the UK and Romania today report the discovery of a variant in the sequence of the human genome associated with risk of developing basal cell carcinoma of the skin (BCC), as well as prostate cancer and glioma, the most serious form of brain cancer.  The study was done in collaboration with Illumina, Inc., and is published today in the online edition of Nature Genetics.

Using Illumina sequencing technology, deCODE scientists determined the sequences of the entire genomes of 457 Icelanders, and identified 16 million single nucleotide polymorphisms (SNPs). Through a combination of SNP genotyping and computational techniques utilizing the extensive Icelandic genealogy, they were able to propagate those 16 million variants into over 40,000 Icelanders for use in this study.

The researchers discovered a single letter variant located in TP53, a gene known to play a central role in tumor biology and for accumulating so called somatic mutations, during the development of cancer in patients.  Until now, however, individuals who are born with defective copies of the gene (germline variants) have been found extremely rarely, only in families with cancer predisposition syndromes, Li Fraumeni syndrome (LFS) and Li-Fraumeni-like syndrome (LFL). The variant found in the present study is an unusual type of mutation that appears to affect the way the gene's messenger RNA is processed; the messenger RNA in patients with the mutant TP53 gene appears to lack proper termination and polyadenylation.

This is the first evidence of a germline variant in TP53 associated with cancer predisposition beyond LFS and LFL. While the mutations causing LFS and LFL syndromes are very rare (occuring 1:5,000 to 1:20,000 births), the variant described in this paper occurs in ~ 1 in 25 individuals in Iceland, and at comparable frequencies in US and UK populations.

"This mutation is one of a growing number of deCODE discoveries of relatively low frequency sequence variants with large effect," said Kari Stefansson, deCODE's CEO and senior author of the study.  "The discovery of such variants is made possible through the breadth and quality of the data that the Icelandic population provides."

Dr. Stefansson emphasized, "We will, together with our collaborators, including Illumina, extend ourselves to turn this discovery into benefit for patients and those at risk of cancer."

BCC is the most common cancer in people of European ancestry. Sun exposure is the primary risk factor for BCC, but genetic predisposition also plays a substantial role.   Until now, no mechanistic causal connection between cancers as diverse as BCC, prostate cancer, glioma, and colorectal adenoma was known.

The paper, "A Germline Variant in the TP53 Polyadenylation Signal Confers Cancer Susceptibility" is published online in Nature Genetics at http://www.nature.com/ng and will appear in an upcoming print edition of the journal.

About deCODE

Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.

In order to most rapidly realize the value of genetics for human health, deCODE is currently partnering with life sciences companies to accelerate their target discovery, validation, and prioritization efforts, yielding improved patient stratification for clinical trials and essential companion diagnostics. In addition, through its CLIA- and CAP-certified laboratory, deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases.  deCODE also licenses its tests, intellectual property, and analytical tools to partner organizations. deCODE's corporate information can be found at http://www.decode.com with information about our genetic testing services at http://www.decodehealth.com and http://www.decodeme.com.

Contact:
Gisli Arnason
+354 570 1825
gisli.arnason@decode.is



'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
2. The New deCODE Map of the Human Genome
3. deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma
4. ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test
5. deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases
6. deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk
7. deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal
8. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
9. Amaizing: Corn genome decoded
10. deCODE Receives Nasdaq Bid Price Deficiency Notice
11. deCODE genetics Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Global ... mutual endorsement of an Asia-Pacific Symposium as other research and development initiatives for potential ... Santiago officials and top Global Stem Cells Group executives began meeting to establish a ...
(Date:4/26/2016)... Calif. (PRWEB) , ... April 27, 2016 , ... ... office of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s ... U.S. and international electrical, mechanical and electromechanical patent applications. He has an electrical ...
(Date:4/26/2016)... Baden-Württemberg (PRWEB) , ... April 26, 2016 , ... ... of laser lithography systems, announces the latest technology innovation for its Volume Pattern ... fulfill tomorrow’s demand for production of advanced photomasks as well as a solution ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
Breaking Biology Technology:
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
Breaking Biology News(10 mins):